pharmaphorum

JULY 5, 2022

The new partnership will apply Mogrify’s cellular reprogramming and bioinformatics expertise to try to identify transcription factors – proteins which can turn specific genes on or off – that can be used to generate new cochlear hair cells. An estimated 1.57

In-Vivo 92

In-Vivo Bioinformatics Genetics Licensing 92

Drug Discovery World

APRIL 29, 2024

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Scienmag

JUNE 22, 2021

Credit: Insilco June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into (..)

Medicine 55

Medicine Clinical Trials Clinical Trials Clinical Development 55

Drug Discovery World

NOVEMBER 30, 2023

Field also covered the capabilities and strategies that enable acceleration of Fc-fusion, Fab fragment and bispecific antibodies through pre-clinical development. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7 kb Influenza A hemagglutinin gene was used as a model system.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion.

Protein 59

Protein Antibody Engineer Scientist 59

pharmaphorum

APRIL 15, 2021

We have a pipeline of novel therapeutics and technological approaches, advancing a diverse array of candidates, including small molecules, biologics and cell and gene therapies, so a lot of the time we are working where there’s little, or no precedent.”. In principle, this goes beyond medicines.

Development 60

Development Manufacturing Production Bioinformatics 60